Consulting agreement under which Dr. Pepose was paid a monthly consulting fee and received 32,000 RSUs and options to purchase 48,000 shares; the Company incurred related consulting expenses in fiscal year 2025
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Consulting agreement under which Dr. Pepose was paid a monthly consulting fee and received 32,000 RSUs and options to purchase 48,000 shares; the Company incurred related consulting expenses in fiscal year 2025
Subscription agreement to purchase 392,157 shares of Common Stock and receive 392,157 warrants in a private offering
Subscription agreement to purchase 784,314 shares of Common Stock and receive 784,314 warrants in a private offering
Investment of $1.0 million in the August 2025 Private Placement
Participation in the August 2025 Private Placement with an investment of $0.1 million
2022 binding letter agreement to collaborate on natural history studies, requiring the Company to provide a total of $2.0 million of funding, superseded in 2025
2025 letter agreement to collaborate on a study of retinal dystrophies; the Company paid $0.3 million in fiscal year 2025 and must fund one more installment of $0.3 million
Funding agreement providing nondilutive funding of up to $2.0 million for the MERTK Program, with $1.0 million disbursed in June 2025, and royalty and milestone payment obligations to RDF
Loading...